
Cytokinetics Inc is a biotechnology business based in the US. Cytokinetics shares (CYTK) are listed on the NASDAQ and all prices are listed in US Dollars. Cytokinetics employs 253 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Cytokinetics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CYTK – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Cytokinetics stock price (NASDAQ: CYTK)
Use our graph to track the performance of CYTK stocks over time.Cytokinetics shares at a glance
Latest market close | $47.25 |
---|---|
52-week range | $17.72 - $48.10 |
50-day moving average | $39.68 |
200-day moving average | $37.57 |
Wall St. target price | $61.58 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.21 |
Buy Cytokinetics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cytokinetics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cytokinetics price performance over time
Historical closes compared with the close of $47.25 from 2022-06-24
1 week (2022-06-17) | 16.44% |
---|---|
1 month (2022-05-27) | 12.85% |
3 months (2022-03-25) | 29.56% |
6 months (2021-12-27) | 3.05% |
1 year (2021-06-25) | 110.00% |
---|---|
2 years (2020-06-26) | 98.78% |
3 years (2019-06-27) | 326.83% |
5 years (2017-06-27) | 253.93% |
Cytokinetics financials
Revenue TTM | $65 million |
---|---|
Gross profit TTM | $-89,510,000 |
Return on assets TTM | -19.5% |
Return on equity TTM | -279.9% |
Profit margin | 0% |
Book value | $1.36 |
Market capitalisation | $4 billion |
TTM: trailing 12 months
Cytokinetics share dividends
We're not expecting Cytokinetics to pay a dividend over the next 12 months.
Have Cytokinetics's shares ever split?
Cytokinetics's shares were split on a 1:6 basis on 24 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics shares which in turn could have impacted Cytokinetics's share price.
Cytokinetics share price volatility
Over the last 12 months, Cytokinetics's shares have ranged in value from as little as $17.72 up to $48.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics's is 1.2246. This would suggest that Cytokinetics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cytokinetics overview
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California. .
Cytokinetics in the news
Shareholders have faith in loss-making Cytokinetics (NASDAQ:CYTK) as stock climbs 20% in past week, taking three-year gain to 329%
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
Frequently asked questions
What percentage of Cytokinetics is owned by insiders or institutions?Currently 4.871% of Cytokinetics shares are held by insiders and 114.16% by institutions. How many people work for Cytokinetics?
Latest data suggests 253 work at Cytokinetics. When does the fiscal year end for Cytokinetics?
Cytokinetics's fiscal year ends in December. Where is Cytokinetics based?
Cytokinetics's address is: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Cytokinetics's ISIN number?
Cytokinetics's international securities identification number is: US23282W6057 What is Cytokinetics's CUSIP number?
Cytokinetics's Committee on Uniform Securities Identification Procedures number is: 23282W100
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert